


Industry:	Pharma		2020	2021F	2022F	2023F
Report Date:	May 20, 2021	Rev Growth	-2.4%	24.1%	26.1%	21.6%
Current Price:	VND71,100	EPS Growth	28.0%	21.8%	29.7%	21.6%
Target Price:	VND80,300	GPM	39.9%	41.4%	41.7%	42.0%
Last Target Price:	VND72,200	NPM	15.3%	15.5%	15.9%	16.1%
Upside to TP:	+12.9%	EV/EBITDA	14.9x	11.7x	9.1x	7.4x
Dividend Yield:	+2.1%	P/CFO	49.6x	16.2x	20.8x	15.9x
TSR:	+15.0%	P/E	25.0x	20.5x	15.8x	13.0x



Market Cap:	USD206mn		IMP	Peers*	VNI
Foreign Room:	USD0	P/E (ttm)	25.2x	17.4x	17.3x
ADTV30D:	USD188,000	P/B (curr)	2.7x	2.6x	2.6x
State Ownership:	22.9%	Net D/E	0.0%	-11.4%	N/A
Outstanding Shares:	66.7 mn	ROE	12.5%	14.6%	15.1%
Fully Diluted Shares:	66.7 mn	ROA	10.5%	10.5%	2.4%
3-yr PEG:	1.0		* Domestic and foreign peers		

Company overview

IMP is a generic pharmaceutical company in Vietnam. Its main products include antibiotics and specific treatment medicines. IMP utilizes advanced technology that meets EU-GMP production standards.

Son Tran
Senior Analyst
son.tran@vcsc.com.vn
+8428 3914 3588 ext. 185

Phap Dang, CFA
Associate Director
phap.dang@vcsc.com.vn
+8428 3914 3588 ext. 143

Strong growth prospects intact, led by hospital channel

- We downgrade our rating from BUY to OUTPERFORM as IMP's share price has rallied 35% in the last three months. That said, we lift our TP by 11% thanks to (1) a 50-bp decrease in our house cost of equity to 12.5% and (2) a rollover of our TP to mid-2022 vs YE2021 as previously.
- We believe IMP's leading production technology (EU-GMP standard) and ample spare capacity along with a supportive policy backdrop that favors high-quality, locally produced drugs in the hospital channel will lead to elevated earnings growth in the next few years.
- We trim our aggregate 2021F-2023F NPAT by 4% due to the late commencement of the new IMP4 factory and a recent resurgence of COVID-19 that will hurt pharmacy and hospital visits.
- We forecast an in-house product revenue CAGR of 25% in 2020-2023F, which will be mainly driven by a 46% CAGR in revenue from the hospital channel. Accordingly, we forecast the hospital channel's contribution to total revenue will widen from 41% in 2020 to 65% in 2023F.
- We forecast NPAT margin will advance from 15.3% in 2020 to 16.1% in 2023F on the back of increases in factory utilization, which will be partly offset by higher marketing expenses given stiffening competition in the pharmacy channel.
- Potential upside: Strategic investor SK Group's technological and distribution support could help IMP to better penetrate the tier-1 segment (highest quality tier in hospitals) and export markets.
- Downside risks to our positive view: Escalation of COVID-19 that would undermine consumer visits to pharmacies and hospitals; heightening competition; unfavorable policy movement.

IMP4's pending EU-GMP approval is facing an extended delay due to COVID-19. Due to COVID-19's disruptions on international travel that prevent European Medicines Agency (EMA) member experts to arrive in Vietnam for the final factory inspection, management expects IMP4 to obtain EU-GMP approval in late 2021 before starting to contribute revenue in mid-2022, which is later than our previous assumption of H2 2021. Therefore, in our revised projections, we lower IMP4's contributions to IMP's total in-house revenue from 3%/8%/14% to 0%/5%/8% in 2021F/2022F/2023F, respectively.

IMP's well-timed stocking and increasing factory utilization to overcome cost pressure from rising active pharmaceutical ingredient (API) prices. Per IMP, most API prices jumped in Q1 2021 with paracetamol (used for painkillers and fever reducers) skyrocketing ~300% YoY. Nonetheless, IMP has already stocked up for production through Q3 2021 (and even up to Q4 2021 for some categories) at favorable prices. In addition, painkillers and fever reducers contribute less than 10% to IMP's revenue. Meanwhile, we forecast the utilization of IMP's EU-GMP factories will pick up from ~25% in 2020 (our estimate) to ~50% in 2023F. Accordingly, we project IMP's in-house product GPM to expand from 41.0% in 2020 to 42.8% in 2023F while its ROIC will climb from 16.3% in 2020 to 27.3% 2023F.


4M 2021: Robust revenue growth from the pharmacy and hospital channels

Figure 1: IMP's 4M 2021 results

VND bn	4M 2020	4M 2021	YoY	VCSC comments
Net revenue	368	401	9%	Pharmacy and hospital revenue increased 14% and 35% YoY, respectively. In the hospital channel, IMP gained market share against imported drugs in the Tier 2 of hospital drug tenders, which was backed by IMP's advanced manufacturing standard (EU-GMP standard) and cost advantages vs imported drugs. The Pharmacy and hospital channels accounted for 63% and 37% of IMP's in-house product revenue in 4M 2021, respectively.
In-house products	329	388	18%	For April 2021 alone, revenue surged 62% YoY to VND105bn (USD4.5mn), which we attribute partly to a low April 2020 base that was hurt by COVID-19's negative impact on traffic to both pharmacies and hospitals. Meanwhile, IMP's winning value in hospital tender reached VND989bn (USD43mn) in 4M 2021 with Tier 1 and Tier 2 (i.e., the two highest drug tiers in hospital tender) accounting for 8% and 89%, respectively. 4M 2021's winning value surpassed VND941bn (USD41mn) that was achieved for full-year 2020.
Others ⁽¹⁾	39	13	-68%	Mostly due to a decrease in OEM revenue generated from Sandoz — a German pharmaceutical company.
Gross profit	150	171	14%	
SG&A	-85	-94	10%	
EBIT	66	77	18%	
Non-operating items	-4	-1	-68%	Abnormal gains from liquidating some fixed assets in 4M 2021, which partly offset financial expenses (i.e., mostly payment discounts and interest expenses).
PBT	62	76	23%	
Gross profit margin	40.8%	42.7%		Blended GPM advanced thanks to a smaller contribution from the low-margin OEM and trading goods segments. Meanwhile, in-house product GPM contracted mostly due to a rebound in promotions for pharmacies.
SG&A/In-house product sales	25.8%	24.1%		Thanks to economies of scale as well as the fact that some marketing activities were held back amid the third wave of COVID-19 that started in late January.
EBIT margin	17.8%	19.3%		
PBT margin	16.8%	19.0%		

Source: IMP, VCSC; ⁽¹⁾ OEM, exports and trading goods

Figure 2: IMP's winning value in hospital tender and hospital revenue (our estimates)



Source: Drug Administration of Vietnam, VCSC (Winning value is a good indicator of future revenue; however, winning value tends to be larger than recognized revenue in a certain year because (1) actual delivery to hospitals depends on the actual demand of the hospitals and (2) winning contracts are typically executed over one to two years)

2021F: We trim our earnings forecast mainly due to COVID-19 resurgence and IMP4's late commencement

Figure 3: VCSC's 2021 forecasts

VND bn	2020	2021F old	2021F new	2021F new YoY	VCSC comments on new 2021F
Net revenue	1,369	1,794	1,699	24%	Pharmacy revenue to grow 10% off a low base and contribute 51% to in-house product revenue.
In-house products ⁽¹⁾	1,280	1,694	1,642	28%	Hospital revenue to surge 55% thanks to IMP's broadening market share in this channel. In 2021, we expect IMP will see more benefits from Circular 15's stipulation that PIC/S-GMP drugs granted by non-ICH members will be replaced by EU-GMP drugs and PIC/S-GMP drugs granted by ICH members. We note that successful bids of PIC/S-GMP drugs granted by non-ICH members before October 2019 — which was when Circular 15 became effective — would continue to be delivered until the contracts expire (these contracts typically span one to two years). We curtail our forecast due to a late commencement of the new IMP4 factory (as mentioned on Page 1) and the recent resurgence of COVID-19 in Vietnam that will hurt pharmacy and hospital visits.
Others ⁽²⁾	90	99	57	-37%	We revise down our forecast as Q1 2021 results trailed our expectation for the reason we mentioned in Figure 1 .
Total gross profits	547	736	703	28%	
In-house products ⁽¹⁾	525	712	691	31%	
Others ⁽²⁾	22	23	12	-44%	
Selling expenses	-213	-286	-271	27%	We expect IMP will intensify its marketing activities from Q2 2021 to stimulate sales and fend off stiffening competition.
G&A expenses	-71	-97	-92	29%	In 2020, IMP imposed strict cost controls — including labor costs. We expect the situation will normalize in 2020.
EBIT	263	353	340	29%	
Non-operating items	-7	-14	-11	57%	Mainly consist of interest expenses and payment discounts.
PBT	255	339	329	29%	
NPAT	210	271	263	25%	
Blended GPM	39.9%	41.0%	41.4%		We expect GPM to narrow in the remaining quarters vs Q1 partly because of expected increases in API costs.
In-house product GPM	41.0%	42.1%	42.0%		Thanks to better utilization at the IMP2 and IMP3 factories, which will be partly offset by a projected increase in API prices.
EBIT margin	19.2%	19.7%	20.0%		
NPAT margin	15.3%	15.1%	15.5%		

Source: IMP, VCSC

⁽¹⁾ We assume all reported revenue deductions and promotional goods are attributed to in-house products

⁽²⁾ OEM, exports and trading goods

Valuation

We maintain our FCFE valuation approach for IMP given its simple business structure, stable revenue stream and expected robust cash generation.

In order to factor in the dilution impact of IMP's ESOP issuances from the perspective of an existing shareholder, we assign our projected FCFE with weightings that reflect the cumulative dilution of projected future ESOP issuances (**Figure 5**). In our five-year forecast period, we assume IMP will issue a 5% ESOP in 2023 based on its track record of carrying out 5% ESOP issuances every three years (the latest completed issuance took place in October 2020).

Figure 4: DCF valuation for IMP

Cost of Equity	Current	Previous	FCFE (Five Year)	VND bn
Beta ⁽¹⁾	0.8	0.8	PV of Free Cash Flows	898
Market risk premium %	9.9%	9.9%	PV of Terminal Val (5.0% g)	4,459
Risk Free Rate %	2.6%	3.1%	PV of FCF and TV	5,357
Cost of Equity %	10.5%	11.0%	- Minority Interest	0
			Equity Value	5,357
			Shares (million)	66.7
			Value per share, VND	80,300

Source: VCSC; ⁽¹⁾ based on median of peer beta (two-year period)

Figure 5: Cash flows

VND bn	2021F	2022F	2023F	2024F	2025F
Net income	231	300	370	455	524
- Capex	-68	-68	-68	-68	-68
+ Depreciation	60	81	101	106	110
- Change in working cap	2	-153	-172	-206	-180
+ Net borrowing	99	-50	-180	0	0
+ ESOP proceeds	-	-	40	-	-
FCFE + ESOP proceeds ⁽¹⁾	325	111	91	287	386
ESOP-adjustment weighting ⁽²⁾	100%	100%	95%	95%	95%
ESOP-adjusted attributed FCFE (1 x 2)	325	111	86	273	368
Present Value of attributed FCFE	309	95	67	192	234
Cumulative PV of attributed FCFE	309	404	471	664	898

Source: VCSC

Figure 6: Sensitivity analysis of our target price for IMP to cost of equity and terminal growth rate, ceteris paribus

Target Price (VND)	Cost of equity (Ke)					
	10.0%	10.5%	11.0%	11.5%	12.0%	
Terminal growth (g)	3.0%	71,600	66,200	61,600	57,500	54,000
	4.0%	82,700	75,600	69,500	64,300	59,800
	5.0%	98,800	88,600	80,300	73,400	67,500
	6.0%	124,000	108,200	95,900	86,000	78,000
	7.0%	169,200	140,700	120,300	105,000	93,000

Source: VCSC

Comparable peers

For peer reference, we look at leading generic pharma companies in India, China and Indonesia as well as the four largest listed pharma companies in Vietnam apart from IMP.


While IMP's current TTM PER is well above the current peer median and as our target price implies 2021F/2022F PERs of 23.2x/17.9x for IMP compared to a peer three-year average TTM PER of 16.4x, we believe our implied earnings multiple premium for IMP vs peers is justified by its strong competitive advantages and earnings growth outlook.

Figure 7: Comparable peers

USD mn Company	Country	Market cap	TTM Net Sales	YoY %	TTM NPAT	YoY %	Net D/E x	ROE %	TTM P/E	LQ P/B
Regional peers										
Aurobindo Pharma	India	8,150	3,208	18.3	399	19.7	0.2	18.4	21.1	3.5
Glenmark Pharmaceuticals	India	2,370	1,467	7.1	109	-16.1	0.7	13.3	22.3	2.9
Beijing SI Pharmaceutical	China	1,990	173	-33.4	58	13.6	-0.3	7.9	32.4	2.5
Shanghai Shyndec	China	1,804	1,947	6.9	108	21.0	0.2	9.1	15.8	1.4
Eris Lifesciences	India	1,337	163	14.5	48	19.8	-0.1	24.7	27.5	6.2
Zhejiang Jingxin Pharmaceu	China	1,183	485	-7.4	101	41.7	-0.4	17.6	11.1	1.9
KPC Pharma	China	1,092	1,188	1.7	83	26.4	-0.2	12.5	12.5	1.5
Guizhou Yibai Pharmaceutic	China	780	524	10.1	35	68.4	0.2	6.8	20.9	1.5
Local peers										
Hau Giang Pharma	Vietnam	545	169	-1.8	33	13.4	-0.5	20.2	17.0	3.3
Pymepharco	Vietnam	257	87	5.0	14	1.3	0.0	15.9	17.9	2.8
Traphaco	Vietnam	123	86	14.5	9	37.8	-0.3	17.7	15.2	2.6
Domesco	Vietnam	69	63	0.2	7	-28.7	-0.2	12.2	9.9	1.2
Median		1,138	329	6.0	53	19.7	-0.1	14.6	17.4	2.6
Average		1,642	797	3.0	84	18.2	-0.1	14.7	18.6	2.6
IMP	Vietnam	206	59	-4.9	9	25.9	0.0	12.5	25.2	2.7

Source: Bloomberg, VCSC (data as of May 20, 2021)

Figure 8: IMP's TTM PER vs peers



Source: Bloomberg, VCSC

Figure 9: Recommendation history (share prices adjusted for share splits – VND/share)



Source: Bloomberg, VCSC

Financial Statements

P&L (VND bn)	2020	2021F	2022F	2023F	B/S (VND bn)	2020	2021F	2022F	2023F
Revenue	1,369	1,699	2,143	2,606	Cash & equivalents	85	160	124	134
COGS	-822	-996	-1,249	-1,511	ST investments	64	200	200	100
Gross Profit	547	703	894	1,095	Accounts receivables	318	331	423	521
Sales & Marketing exp	-213	-271	-346	-424	Inventories	424	396	496	600
General & Admin exp	-71	-92	-114	-136	Other current assets	91	132	167	203
Operating Profit	263	340	434	535	Total Current assets	982	1,218	1,409	1,558
Financial income	10	10	16	13	Fixed assets, gross	1,463	1,531	1,599	1,667
Financial expenses	-20	-26	-27	-27	- Depreciation	-438	-498	-579	-680
- o/w interest expense	-5	-11	-8	-3	Fixed assets, net	1,026	1,034	1,020	987
Associates	0	0	0	0	LT investments	52	52	52	52
Net other income/(loss)	3	5	3	3	LT assets other	37	51	64	78
Profit before Tax	255	329	426	525	Total LT assets	1,114	1,136	1,136	1,117
Income Tax	-46	-66	-85	-105	Total Assets	2,096	2,354	2,546	2,675
NPAT before MI	210	263	341	420	Accounts payable	60	81	113	136
Minority Interest	0	0	0	0	Short-term debt	131	50	0	0
NPAT less MI, reported	210	263	341	420	Other ST liabilities	156	162	205	249
NPAT less MI, adjusted⁽¹⁾	210	263	341	420	Total current liabilities	347	294	318	385
EBITDA	316	400	515	637	Long-term debt	0	180	180	0
EPS reported, VND	2,847	3,468	4,498	5,471	Other LT liabilities	19	19	19	19
EPS adjusted ⁽¹⁾ , VND	2,847	3,468	4,498	5,471	Total Liabilities	366	493	517	404
EPS diluted, adj ⁽¹⁾ , VND	2,847	3,468	4,498	5,471	Preferred equity	0	0	0	0
DPS, VND	1,500	2,000	2,500	3,000	Paid-in capital	667	667	667	700
DPS/EPS (%)	52.7%	57.7%	55.6%	54.8%	Share premium	507	507	507	514
⁽¹⁾ Adjusted for one-offs					Retained earnings	205	337	503	706
RATIOS	2020	2021F	2022F	2023F	Other equity	351	351	351	351
Growth					Minority interest	0	0	0	0
Revenue growth	-2.4%	24.1%	26.1%	21.6%	Total equity	1,730	1,862	2,028	2,271
Op profit (EBIT) growth	29.3%	29.4%	27.6%	23.4%	Liabilities & equity	2,096	2,354	2,546	2,675
PBT growth	26.2%	28.7%	29.7%	23.2%	Y/E shares out, mn	66.7	66.7	66.7	70.0
EPS growth, adjusted	28.0%	21.8%	29.7%	21.6%	Y/E treasury shares, mn	0.0	0.0	0.0	0.0
Profitability					CASH FLOW (VND bn)	2020	2021F	2022F	2023F
Gross Profit Margin	39.9%	41.4%	41.7%	42.0%	Beginning Cash Balance	75	85	160	124
Op Profit, (EBIT) Margin	19.2%	20.0%	20.2%	20.5%	Net Income	210	263	341	420
EBITDA Margin	23.1%	23.5%	24.0%	24.4%	Dep'n & amortization	53	60	81	101
NPAT-MI Margin, adj,	15.3%	15.5%	15.9%	16.1%	Change in Working Cap	-142	2	-153	-172
ROE	12.7%	14.6%	17.5%	19.5%	Other adjustments	-25	-32	-41	-50
ROA	10.6%	11.8%	13.9%	16.1%	Cash from Operations	96	293	229	299
Efficiency					Capital Expenditures, net	-112	-68	-68	-68
Days Inventory On Hand	171.9	150.2	130.3	132.4	Investments, net	-47	-150	-13	86
Days Accts, Receivable	74.3	69.7	64.2	66.1	Cash from Investments	-159	-218	-81	18
Days Accts, Payable	30.7	26.6	26.3	28.1	Dividends Paid	-49	-100	-133	-167
Cash Conversion Days	215.6	193.3	168.2	170.4	Δ in Share Capital	30	0	0	40
Liquidity					Δ in ST debt	93	-81	-50	0
Current Ratio x	2.8	4.1	4.4	4.1	Δ in LT debt	0	180	0	-180
Quick Ratio x	1.6	2.8	2.9	2.5	Other financing C/F	0	0	0	0
Cash Ratio x	0.2	0.5	0.4	0.3	Cash from Financing	74	-1	-183	-307
Debt / Assets	0.1	0.1	0.1	-	Net Change in Cash	10	74	-36	10
Debt / Capital	0.1	0.1	0.1	-	Ending Cash Balance	85	160	124	134
Net Debt / Equity	-0.0	-0.1	-0.1	-0.1					
Interest Coverage x	48.6	30.6	55.5	163.0					

Source: Company data, VCSC

VCSC Rating System

Stock ratings are set based on projected total shareholder return (TSR), defined as (target price – current price)/current price + dividend yield, and are not related to market performance.

Equity rating key	Definition
BUY	If the projected TSR is 20% or higher
OUTPERFORM	If the projected TSR is between 10% and 20%
MARKET PERFORM	If the projected TSR is between -10% and 10%
UNDERPERFORM	If the projected TSR is between -10% and -20%
SELL	If the projected TSR is -20% or lower
NOT RATED	The company is or may be covered by the Research Department but no rating or target price is assigned either voluntarily or to comply with applicable regulation and/or firm policies in certain circumstances, including when VCSC is acting in an advisory capacity in a merger or strategic transaction involving the company.
RATING SUSPENDED, COVERAGE TERMINATED	A rating may be suspended, or coverage terminated, if fundamental information is deemed insufficient to determine a target price or investment rating or due to a reallocation of research resources. Any previous investment rating and target price are no longer in effect.

Unless otherwise specified, these performance parameters are set with a 12-month horizon. Movement in share prices may cause a temporary mismatch between the latest published rating and projected TSR for a stock based on its market price and the latest published target price.

Target prices are generally based on the analyst's assessment of the stock's fair value over a 12-month horizon. However, the target price may differ from the analyst's fair value if the analyst believes that the market will not price the stock in line with assessed fair value over the specified time horizon.

Risks: Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

Disclaimer

Analyst Certification of Independence

I, Son Tran, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities or issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking.

VCSC and its officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). VCSC may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment.

Copyright 2013 Viet Capital Securities Company "VCSC". All rights reserved. This report has been prepared on the basis of information believed to be reliable at the time of publication. VCSC makes no representation or warranty regarding the completeness and accuracy of such information. Opinions, estimates and projection expressed in this report represent the current views of the author at the date of publication only. They do not necessarily reflect the opinions of VCSC and are subject to change without notice. This report is provided, for information purposes only, to institutional investors and retail clients of VCSC in Vietnam and overseas in accordance to relevant laws and regulations explicit to the country where this report is distributed, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction. Investors must make their investment decisions based upon independent advice subject to their particular financial situation and investment objectives. This report may not be copied, reproduced, published or redistributed by any person for any purpose without the written permission of an authorized representative of VCSC. Please cite sources when quoting.

U.K. and European Economic Area (EEA): Unless specified to the contrary, issued and approved for distribution in the U.K. and the EEA by VCSC issued by VCSC has been prepared in accordance with VCSC's policies for managing conflicts of interest arising as a result of publication and distribution of investment research. Many European regulators require a firm to establish, implement and maintain such a policy. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction. **Australia:** This material is issued and distributed by VCSC in Australia to "wholesale clients" only. VCSC does not issue or distribute this material to "retail clients". The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of VCSC. For the purposes of this paragraph the terms "wholesale client" and "retail client" have the meanings given to them in section 761G of the Corporations Act 2001. **Hong Kong:** The 1% ownership disclosure as of the previous month end satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from two months prior.) **Japan:** There is a risk that a loss may occur due to a change in the price of the shares in the case of share trading, and that a loss may occur due to the exchange rate in the case of foreign share trading. In the case of share trading, VCSC will be receiving a brokerage fee and consumption tax (shouhizei) calculated by multiplying the executed price by the commission rate which was individually agreed between VCSC and the customer in advance. **Korea:** This report may have been edited or contributed to from time to time by affiliates of VCSC. **Singapore:** VCSC and/or its affiliates may have a holding in any of the securities discussed in this report; for securities where the holding is 1% or greater, the specific holding is disclosed in the Important Disclosures section above. **India:** For private circulation only, not for sale. **Pakistan:** For private circulation only, not for sale. **New Zealand:** This material is issued and distributed by VCSC in New Zealand only to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money. VCSC does not issue or distribute this material to members of "the public" as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of VCSC. **Canada:** The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence. **Dubai:** This report has been issued to persons regarded as professional clients as defined under the DFSA rules. **United States:** This research report prepared by VCSC is distributed in the United States to Major US Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) only by Decker&Co, LLC, a broker-dealer registered in the US (registered under Section 15 of Securities Exchange Act of 1934, as amended). All responsibility for the distribution of this report by Decker&Co, LLC in the US shall be borne by Decker&Co, LLC. All resulting transactions by a US person or entity should be effected through a registered broker-dealer in the US. This report is not directed at you if VCSC Broker or Decker&Co, LLC is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Decker&Co, LLC and VCSC is permitted to provide research material concerning investment to you under relevant legislation and regulations.

Contacts

Corporate

www.vcsc.com.vn

Head Office

Bitexco Financial Tower, 2 Hai Trieu Street
District 1, HCMC
+84 28 3914 3588

Transaction Office

10 Nguyen Hue Street
District 1, HCMC
+84 28 3914 3588

Research

Research Team: +84 28 3914 3588
research@vcsc.com.vn

Banks, Securities and Insurance

Long Ngo, Associate Director, ext 123

- Truc Ngo, Analyst, ext 116
- Tu Hoang, Analyst, ext 139

Consumer and Pharma

Phap Dang, Associate Director, ext 143

- Ha Dao, Senior Analyst, ext 194
- Son Tran, Senior Analyst, ext 185
- Vinh Bui, Analyst, ext 191

Real Estate, Construction and Materials

Hong Luu, Senior Manager, ext 120

- Vy Nguyen, Manager, ext 147
- Duc Pham, Analyst, ext 174

Retail Client Research

Duc Vu, Senior Manager, ext 363

- Trung Nguyen, Senior Analyst, ext 129
- Anh Tong, Analyst, ext 363

Institutional Sales and Brokerage

& Foreign Individuals

Dung Nguyen

+84 28 3914 3588, ext 136
dung.nguyen@vcsc.com.vn

Hanoi Branch

109 Tran Hung Dao
Hoan Kiem District, Hanoi
+84 24 6262 6999

Transaction Office

236-238 Nguyen Cong Tru Street
District 1, HCMC
+84 28 3914 3588

Alastair Macdonald, Head of Research, ext 105

alastair.macdonald@vcsc.com.vn

Macro

Luong Hoang, Manager, ext 364

- Nguyen Truong, Senior Analyst, ext 132

Oil & Gas and Power

Duong Dinh, Senior Manager, ext 140

- Tram Ngo, Manager, ext 135
- Nghia Le, Analyst, ext 181
- Duc Le, Analyst, ext 196

Industrials and Transportation

Nam Hoang, Manager, ext 124

- Dang Thai, Senior Analyst, ext 149

Retail & Corporate Brokerage

Ho Chi Minh & Hanoi

Quynh Chau

+84 28 3914 3588, ext 222
quynh.chau@vcsc.com.vn